AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02022709
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Trial: NCT02022709
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Trial: NCT02022709
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Trial: NCT01106989
Drug: Heated lidocaine/tetracaine patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
Trial: NCT00002493
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00619944
Drug: Lumefantrine - lopinavir/ritonavir drug interaction
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
Trial: NCT00619944
Drug: Lumefantrine only arm
RxNorm normalized name: Lumefantrine
DrugBank: Lumefantrine (DB06708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
Trial: NCT00346619
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00991809
Drug: Alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mcg/kg IM
Trial: NCT00991809
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg IM
Trial: NCT00497900
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D (cholecalciferol) tablets and rocaltrol
Trial: NCT03470350
Drug: Galunisertib
RxNorm normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with capecitabine and galunisertib
Trial: NCT00551096
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
Trial: NCT03376932
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
Trial: NCT03376932
Drug: Albuterol/salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.
Trial: NCT01132352
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Trial: NCT02735603
Drug: Naltrexone HCl/bupropion HCl
RxNorm normalized name: naltrexone HCl/bupropion HCl 8 mg-90 mg ORAL TABLET, EXTENDED RELEASE
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl/bupropion HCl extended-release tablet.
Trial: NCT02735603
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin tablet.
Trial: NCT03420742
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup.
Trial: NCT03420742
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib tablets.
Trial: NCT02922946
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDAC (histone deacetylase) inhibitor
Trial: NCT01345448
Drug: Brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.1% Brimonidine Lotion, dosed once.
Trial: NCT00005852
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005852
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03758261
Drug: Paravertebral nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
Trial: NCT03758261
Drug: Erector Spinae nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
Trial: NCT00856323
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
Trial: NCT01642550
Drug: RM-131
RxNorm normalized name: morphine sulfate Rectal Suppository [RMS]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
Trial: NCT02039011
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Trial: NCT02039011
Drug: Indacaterol and tiotropium
RxNorm normalized name: indacaterol and mometasone
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Trial: NCT01760577
Drug: Botulinum Toxin A (Allergan, Inc, Irvine CA)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: patients received intraarticular injections by the same experienced physician using aseptic procedures.
Trial: NCT01760577
Drug: Hyalgan (Hyalgan, Fidia , Italy)
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
Trial: NCT02514343
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1ml of 10% magnesium sulfate with 1.5 ml of sterile water
Trial: NCT02514343
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
Trial: NCT01074073
Drug: Lurasidone HCl
RxNorm normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast.
Trial: NCT00895362
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
Trial: NCT00895362
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
Trial: NCT00459940
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04169178
Drug: HLX55
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
Trial: NCT03770858
Drug: Crisaborole
RxNorm normalized name: Crisaborole
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
Trial: NCT00905190
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mg one time
Trial: NCT00066326
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00066326
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00529360
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
Trial: NCT00529360
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
Trial: NCT00432393
Drug: levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00308334
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg po TID X 14 days
Trial: NCT02042287
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral antibiotic
Trial: NCT01904721
Drug: Bimatoprost Solution 1
RxNorm normalized name: Bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Trial: NCT01904721
Drug: Bimatoprost Solution 2
RxNorm normalized name: Bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Trial: NCT01904721
Drug: Bimatoprost Vehicle
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Trial: NCT00335166
Drug: Pardaprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-42 mg
Trial: NCT00335166
Drug: pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5-4.5 mg
Trial: NCT01419119
Drug: Cholecalciferol high dose at Vitamin D deficiency
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
Trial: NCT01419119
Drug: Cholecalciferol median dose at Vitamin D insufficiency
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
Trial: NCT01419119
Drug: Cholecalciferol low dose at Vitamin D deficiency
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
Trial: NCT01419119
Drug: Cholecalciferol median dose at sufficient Vitamin D level
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU daily i.e. 3 drops orally once daily for 12 weeks
Trial: NCT00209937
Drug: Gaboxadol
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01978665
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: similar size tablets
Trial: NCT00123539
Drug: Estrogen Replacement Therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00981903
Drug: Tinzaparin sodium
RxNorm normalized name: Tinzaparin Sodium
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection 175 U/Kg/day
Trial: NCT01951898
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/day, once a daily after dinner, for 28dyas
Trial: NCT00006519
Drug: Capravirine
RxNorm normalized name: Capravirine
DrugBank: Capravirine (DB08502)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01518387
Drug: Lanthanum Carbonate (BAY77-1931)
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00295646
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/d
Trial: NCT00295646
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/d
Trial: NCT01907607
Drug: PD 0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day.
Trial: NCT00503425
Drug: Rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg IV on days 1 and 15
Trial: NCT01525823
Drug: BMS-754807 (IGR-IR/IR Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: BMS-754807 (DB15399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
Trial: NCT01525823
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
Trial: NCT02138812
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
Trial: NCT00442923
Drug: Coreg
RxNorm normalized name: Coreg
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00720577
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg., tablets, 1 tablet once daily
Trial: NCT00720577
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg, tablet, 1 tablet once daily
Trial: NCT04273165
Drug: Etravirine Tablets
RxNorm normalized name: Etravirine Tablets
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily etravirine BID with 100 or 200 tablets for 4 months
Trial: NCT01595529
Drug: Cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
Trial: NCT01595529
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 50mg/kg/day in 3 divided doses
Trial: NCT01595529
Drug: Trimethoprim/Sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
Trial: NCT00382317
Drug: Iobitridol
RxNorm normalized name: iobitridol
DrugBank: Iobitridol (DB12407)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02626936
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Trial: NCT02626936
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Trial: NCT04078204
Drug: Butylphthalide Soft Capsules
RxNorm normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
Trial: NCT01073748
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of paracetamol 15mg/kg.
Trial: NCT02073812
Drug: RPX7009 and RPX2014
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
Trial: NCT02855658
Drug: SS-1
RxNorm normalized name: ISS-1018
DrugBank: ISS-1018 (DB05463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
Trial: NCT03555877
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
Trial: NCT03555877
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg once daily as indicated in the SmPC
Trial: NCT03555877
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,5mg once daily as indicated in the SmPC
Trial: NCT03555877
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg once daily as indicated in the SmPC
Trial: NCT03555877
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
Trial: NCT00447967
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
Trial: NCT00447967
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles